DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Trastuzumab deruxtecan shrank tumours in half of patients with HER2-positive gastric cancer that had progressed after trastuzumab, compared with 14 percent on chemotherapy, and lengthened survival by over four months.
Overview
Randomised phase 2 trial in Japan and South Korea of 187 patients with HER2-positive advanced gastric or junctional adenocarcinoma after at least two prior regimens including trastuzumab, randomised 2:1 to trastuzumab deruxtecan 6.4 mg/kg or physician's choice of irinotecan or paclitaxel.
Objective response was 51 versus 14 percent and median overall survival 12.5 versus 8.4 months (hazard ratio 0.59); interstitial lung disease occurred in 10 percent, with myelosuppression as the other main toxicity.
- Objective response 51 percent vs 14 percent.
- Median overall survival 12.5 vs 8.4 months; hazard ratio 0.59.
Trastuzumab deruxtecan is the standard second- or third-line treatment for HER2-positive gastric cancer, later confirmed against ramucirumab-paclitaxel in DESTINY-Gastric04.
- Asian population; the Western DESTINY-Gastric02 study showed a lower response rate.
- Interstitial lung disease requires monitoring.
Similar pages
not linked directly; found by shared links- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
- Key paperDESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Shares Trastuzumab deruxtecan, Trastuzumab, New England Journal of Medicine.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
- Key paperAPT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan.
- Key paperKEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Shares HER2-positive gastric cancer, Trastuzumab.
- PairingHER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.